Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Simple Summary Glioblastoma multiforme is one of the hardest-to-treat brain tumors, often
resistant to conventional treatments such as chemotherapy and radiation therapy. Despite …

The efficacy of chemotherapy is one of the main challenges in cancer treatment and one of
the major obstacles to overcome in achieving lasting remission and a definitive cure in …

Cancer stem cells (CSCs), known also as tumor-initiating cells, are quiescent, pluripotent,
self-renewing neoplastic cells that were first identified in hematologic tumors and soon after …

For glioblastoma, the tumor microenvironment (TME) is pivotal to support tumor progression
and therapeutic resistance. TME consists of several types of stromal, endothelial and …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Glioblastomas (GBM) are highly aggressive primary brain tumors. Complex and dynamic
tumor microenvironment (TME) plays a crucial role in the sustained growth, proliferation, and …

Glioblastoma multiforme (GBM) is among the most incurable cancers. GBMs survival rate
has not markedly improved, despite new radical surgery protocols, the introduction of new …

Glioblastoma (GBM) is the most common and malignant primary brain cancer in adults.
Without treatment the mean patient survival is approximately 6 months, which can be …

A growing body of evidence suggests that long-chain non-coding RNA (lncRNA) plays an
important role in the malignant biological behavior and drug resistance of glioblastoma …